赛诺菲药厂季度少赚7% 续与葛兰素史克研发新冠疫苗
法国赛诺菲药厂(Sanofi)公布首季业绩。季度纯利15.66亿欧元,按年跌7%。每股季度纯利1.25欧元,经调整後为1.61欧元。季度收入85.91亿欧元,按年跌4.3%。
特殊护理药度销售按年升15%至28.91亿欧元,其中Dupixent湿疹针季度销售10.47亿欧元,按年升46%。疫苗销售按年升5%至9.15亿欧元。但一般药物销售按年跌3.8%至36.72亿欧元。
公司表示,与葛兰素史克研发的新冠疫苗将於下月有第二阶段测试结果。公司目前协助辉瑞与BioNTech、强生及Moderna生产疫苗,亦与美国Translate Bio合作第二款新冠疫苗,料明年可推出。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.